Medizone International, Inc. (OTCBB:MZEI) announced today that it has retained The Eversull Group for Financial Public Relations, Investor Relations and Shareholder Services Consulting.
Medizone International, Inc. is a research and development company engaged in developing its AsepticSure™ System to decontaminate and sterilize hospital surgical suites, emergency rooms, intensive care units, schools and other critical infrastructure. A government variant is being developed for bio-terrorism counter measures.
Current research is being conducted at Medizone’s dedicated laboratories located in Innovation Park, Queen’s University in Kingston, Ontario, Canada.
The Eversull Group, based in Frisco, Texas, a suburb of Dallas, has been in business since 1997 and over that time, has been very successful in getting national and international newspaper, magazine and television press coverage, financing, and individual and institutional investors for their clients, and has a good track record moving OTCBB companies to a primary stock exchange.
Edwin Marshall, Chairman and CEO of Medizone, remarked, “The Eversull Group was recommended to us by a trusted associate and after some due diligence, we believe they are the perfect firm to work with as we bring Medizone to new levels. With our patent applications under the international Patent Corporation Treaty filed and anticipated expansion of our commercial interests beyond hospital sterilization, we expect to generate a lot of attention in the investment community and public interest sector. We believe The Eversull Group’s experience and track record suggests they will do a professional job in helping us grow the company relative to financial and media coverage, shareholder relations and an eventual move to a major exchange.”
For more information on Medizone International, please view: www.medizoneint.com.
Starting immediately, shareholder inquiries should be directed to (972) 571-1624.
This Press Release contains certain forward looking statements that involve substantial risks and uncertainties, including, but not limited to, the results of ongoing clinical studies, economic conditions, product and technology development, production efficiencies, product demand, competitive products, competitive environment, successful testing and government regulatory issues. Additional risks are identified in the company’s filings made with the Securities and Exchange Commission.
Investor Relations Contact:
The Eversull Group, Inc.